Sign in
TerminatedPhase 1

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Boston, Columbus, Duarte, Houston, and Tampa, United StatesSee the 5 sitesAlso in 6 other countries, 7 sites
Status
Terminated
Phase
Phase 1
People taking part
33 people enrolled
Started
18 Jun 2021
Ended
19 Apr 2024
Type of study
Interventional, 5 groups
Treatments tested
  • MBG453
  • NIS793
  • canakinumab
Record updated
10 October 2025
Why it stopped
Business reasons

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Signed informed consent must be obtained prior to participation in the study
  • Patients must be ≥ 18 years of age at the time of signing the informed consent form (ICF)
  • Patients must have a diagnosis prior to participation in the study of IPSS-R very low, low, or intermediate risk MDS with ≤10% bone marrow blasts and one or more of the following:; Symptomatic anemia with hemoglobin <10 g/dL that has relapsed after or is refractory to ESAs (or the patient is intolerant to ESAs); Symptomatic anemia with hemoglobin <10 g/dL) that is ESA-naive with EPO level ≥ 500 /uL; Thrombocytopenia with platelets <30,000/uL or with clinically significant bleeding or bruising and platelets <50,000/uL; Neutropenia with an absolute neutrophil count (ANC) <500/ µL or with recurrent and/or severe infections and an ANC that is <1000/ µL and amenable to response assessments by International Working Group (IWG) response criteria in myelodysplasia (Cheson et al 2006)
  • Patients who are refractory to, intolerant of, or ineligible/unable to receive SOC therapeutic options including lenalidomide
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2
  • Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to the institutions' guidelines and be willing to undergo a bone marrow aspirate and/or biopsy at screening, during and at the end of therapy on this study -

Who cannot take part

  • Systemic antineoplastic therapy (including cytotoxic chemotherapy, alpha-interferon, kinase inhibitors or other targeted small molecules, and toxin-immunoconjugates) or any experimental therapy within 14 days or 5 half-lives, whichever is longer, before the first dose of study treatment
  • Use of hematopoietic colony-stimulating growth factors (e.g. G-CSF, GM-CSF, M-CSF), thrombopoietin mimetics or ESAs anytime ≤ 2 weeks (or 5 half-lives, whichever is longer) prior to start of study treatment
  • Systemic chronic corticosteroid therapy (>10 mg/day prednisone or equivalent) or any immunosuppressive therapy within 7 days of first dose of study treatment. Topical, inhaled, nasal and ophthalmic steroids are allowed
  • History of hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical classes
  • For arms containing canakinumab: Patients with ANC < 500 /µL
  • Patients with chronic myelomonocytic leukemia (CMML) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN)

Where in United States

Also in 6 other countries, 7 sites

  • Massachusetts General HospitalBoston, United States
  • The Ohio State University -Wexner Medical CenterColumbus, United States
  • City Of Hope National Med Center OncologyDuarte, United States
  • MD Anderson Cancer Center/University of Texas MD AndersonHouston, United States
  • H Lee Moffitt Cancer Center and Research InstituteTampa, United States

About the trial

What the trial wants to find out

The purpose of this study was to characterize the safety, tolerability and confirm the dose for select single agents and combinations in patients with lower risk (very low, low, and intermediate risk) MDS.

The 5 groups in the trial

  • Arm 1: MBG453 single agentTreatment being tested

    Treatment with MBG453 single agent Q4W to confirm safety and tolerability of RD.

    Treatment: MBG453

  • Arm 2: NIS793 single agentTreatment being tested

    Treatment with NIS793 single agent Q3W to establish RD in this indication and confirm safety and tolerability.

    Treatment: NIS793

  • Arm 3: canakinumab single agentTreatment being tested

    Treatment with single agent canakinumab Q4W to confirm safety and tolerability of RD.

    Treatment: canakinumab

  • Arm 4: MBG453 + NIS793 combinationTreatment being tested

    Treatment with combination of MBG453 and NIS793 Q3W to confirm safety and tolerability of combination RD.

    Treatment: MBG453 and NIS793

  • Arm 5: MBG453 + canakinumab combinationTreatment being tested

    Treatment with MBG453 + canakinumab combination Q4W to confirm safety and tolerability of combination RD.

    Treatment: MBG453 and canakinumab

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome
Record updated
10 October 2025